olintatug tesirine (ADCT-901) / Overland ADCT BioPharma - LARVOL DELTA

ADCT-901-101: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: ADC Therapeutics S.A. | Active, not recruiting ➔ Completed | N=132 ➔ 30 | Trial completion date: Apr 2025 ➔ Sep 2024 | Trial primary completion date: Apr 2024 ➔ Sep 2024

Enrollment change • Monotherapy • Trial completion • Trial completion date • Trial primary completion date • Breast Cancer • Cholangiocarcinoma • Oncology • Ovarian Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

ADCT-901-101: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=132 | Active, not recruiting | Sponsor: ADC Therapeutics S.A. | Recruiting ➔ Active, not recruiting

Enrollment closed • Metastases • Monotherapy • Breast Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

ADC Therapeutics Provides Business Updates (GlobeNewswire) - "ADCT-901 (targeting KAAG1): The Company has decided to discontinue this program due to limited signs of efficacy in the dose escalation phase and to reallocate capital to prioritized programs."

Discontinued • Oncology • Solid Tumor

ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) - "ADCT-601 (targeting AXL): Initial data from Phase 1 study in 1H 2024; ADCT-901 (targeting KAAG1): Initial data from Phase 1 study in 1H 2024; ADCT-602 (targeting CD22): Additional data from Phase 1 study in 1H 2024."

P1 data • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Oncology • Solid Tumor

ADCT-901-101: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: ADC Therapeutics S.A. | N=76 ➔ 132

Enrollment change • Metastases • Monotherapy • Breast Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) - "ADCT-901 (targeting KAAG1): Initial data from Phase 1 study in 1H 2024. ADCT-601 (targeting AXL): Initial data from Phase 1 study in 1H 2024. ADCT-602 (targeting CD22): Additional data from Phase 1 study in 1H 2024....R&D expenses were $31.9 million for the quarter ended June 30, 2023, compared to $48.5 million for the same quarter in 2022. R&D expenses decreased due to less investment in Cami (camidanlumab tesirine) due to the completion of the Phase 2 study in 2022 and the Company’s decision to seek a partner to progress the program, as well as less investment in other development programs."

Commercial • P1 data • Oncology • Solid Tumor

ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (Businesswire) - "Upcoming Expected Milestones: ZYNLONTA...Complete enrollment of the LOTIS-5 study in 2024; Preliminary safety and efficacy data from the LOTIS-9 study in 2024; Preliminary safety and efficacy data from the LOTIS-7 study in 2024....ADCT-901 (targeting KAAG1): Preliminary data from Phase 1 dose escalation study in 1H 2024. ADCT-601 (targeting AXL): Preliminary data from Phase 1 dose escalation/expansion study in 1H 2024."

P1 data • P2 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

ADCT-901-101: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=76 | Recruiting | Sponsor: ADC Therapeutics S.A. | Terminated ➔ Recruiting | Trial completion date: Nov 2022 ➔ Apr 2025 | Trial primary completion date: Nov 2022 ➔ Apr 2024

Enrollment open • Metastases • Monotherapy • Trial completion date • Trial primary completion date • Breast Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

ADCT-901-101: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=78 | Terminated | Sponsor: ADC Therapeutics S.A. | Trial completion date: Apr 2025 ➔ Nov 2022 | Recruiting ➔ Terminated | Trial primary completion date: Apr 2024 ➔ Nov 2022

Metastases • Monotherapy • Trial completion date • Trial primary completion date • Trial termination • Breast Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

First-in-human, phase 1, open-label, dose-escalation, dose-expansion study of ADCT-901 as monotherapy in patients with select advanced solid tumors. (ASCO 2022) - P1 | "The study opened for recruitment in September 2021; enrollment is ongoing. Funding: ADC Therapeutics; medical writing: CiTRUS Health Group."

Clinical • Monotherapy • P1 data • Biliary Cancer • Breast Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Kidney Cancer • Oncology • Ovarian Cancer • Prostate Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer

ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates (Businesswire) - "Upcoming Expected Milestones - Hematology Franchise - ZYNLONTA: Present LOTIS-5 safety lead-in data at an upcoming medical meeting in 2H 2022; Receive a regulatory decision for third-line DLBCL from the Committee for Medicinal Products for Human Use (CHMP), a committee of the European Medicines Agency (EMA), by 1Q 2023. Cami: Meet with the U.S. Food and Drug Administration (FDA) for HL pre-Biologics License Application (BLA) meeting in September 2022; Complete BLA submission for HL to the FDA in 2H 2023. Solid Tumor Franchise - Cami (targeting CD25): Preliminary results of safety and clinical activity are anticipated in 2023 for the Phase 1b solid tumor trial of Cami in combination with pembrolizumab. ADCT-901 (targeting KAAG1): Preliminary results of safety and tumor response for the Phase 1 dose escalation trial in multiple solid tumors are anticipated in 2023."

BLA • European regulatory • FDA event • P1 data • P3 data • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline (Businesswire) - "During the webcast, Chris Martin, PhD, Chief Executive Officer, Patrick van Berkel, PhD, Senior Vice President of Research & Development, and Joseph Camardo, MD, Chief Medical Officer, will discuss the broad applicability and flexibility of the Company’s novel ADC technology and provide a deep dive on its portfolio of solid tumor programs including three clinical-stage assets (Cami, ADCT-901, and ADCT-601); ADCT-701, which is approaching the clinic; and a newly disclosed program, ADCT-212, an ADC targeting PSMA with potential utility in metastatic castrate-resistant prostate cancer (mCRPC)."

Clinical • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor

ADC Therapeutics Doses First Patient in Phase 1 Clinical Trial of ADCT-901 in Advanced Solid Tumors (Businesswire) - “ADC Therapeutics SA…announced the first patient has been dosed in the Phase 1 clinical trial evaluating ADCT-901, targeting kidney associated antigen 1 (KAAG1), in patients with selected advanced solid tumors with high unmet medical needs.”

Trial status • Oncology • Solid Tumor

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1; N=70; Recruiting; Sponsor: ADC Therapeutics S.A.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Monotherapy • Breast Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • MRI

ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire) - “Earlier-Stage Pipeline: Initiate Phase 1 study of ADCT-901, targeting KAAG1, in the second half of 2021; Initiate a Phase 1b combination study of ADCT-601 (mipasetamab uzoptirine), targeting AXL, in multiple solid tumors in the first half of 2022.”

New P1 trial • Oncology • Solid Tumor

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors (clinicaltrials.gov) - P1; N=70; Not yet recruiting; Sponsor: ADC Therapeutics S.A.

Clinical • Monotherapy • New P1 trial • Breast Cancer • Cholangiocarcinoma • Gastrointestinal Cancer • Oncology • Ovarian Cancer • Renal Cell Carcinoma • Solid Tumor • Triple Negative Breast Cancer • MRI

ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates (Businesswire) - "2021 Expected Milestones: Report interim results from the pivotal Phase 2 clinical trial of Cami in HL in the second quarter of 2021; File Investigational New Drug (IND) application for ADCT-901, targeting KAAG1 in the second quarter of 2021; Initiate a Phase 1b combination study of ADCT-601, targeting AXL, in multiple solid tumors in the first half of 2022."

IND • New P1 trial • P2 data • Hematological Malignancies • Hodgkin Lymphoma • Oncology • Solid Tumor

ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates (Businesswire) - “Initiate a Phase 1b combination study of ADCT-601, targeting AXL, in multiple solid tumors in the second half of 2021. File Investigational New Drug (IND) application for ADCT-901, targeting KAAG1, in the first half of 2021."

IND • New P1 trial • Oncology • Solid Tumor

ADC Therapeutics and Overland Pharmaceuticals Announce Formation of Overland ADCT BioPharma to Develop and Commercialize Lonca and other ADCs for Hematologic and Solid Tumor Indications in Greater China and Singapore (Businesswire) - "ADC Therapeutics SA...and Overland Pharmaceuticals...today announced that they have jointly formed a new company, Overland ADCT BioPharma (CY) Limited, to develop and commercialize four of ADC Therapeutics’ antibody drug conjugate (ADC) product candidates for difficult-to-treat hematologic and solid tumors – loncastuximab tesirine (Lonca), ADCT-601, ADCT-602 and ADCT-901 – in greater China and Singapore...'As we prepare for the potential U.S. launch of Lonca in 2021...'"

Launch US • M&A • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Oncology • Solid Tumor